Adial Pharmaceuticals, Inc. Proceeds from Contributed Capital
Adial Pharmaceuticals, Inc. (ADIL) reported Proceeds from Contributed Capital of $2.02 million for the 6-month period ending 2023-06-30, per its 10-Q/A filed 2023-10-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromContributedCapital · last filed 2023-10-30
- 2023-06-30: Proceeds from Contributed Capital 6 month $2.02M.
| Period end | Proceeds from Contributed Capital 6 month |
|---|---|
| 2023-06-30 | $2.02M 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |